Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
3.
Exp Ther Med ; 12(3): 1591-1598, 2016 Sep.
Article in English | MEDLINE | ID: mdl-27588080

ABSTRACT

The association between inflammatory cytokines and the risk of post-stroke depression (PSD) remains unclear. The aim of the present study was to investigate this association and the effect of PSD on the outcomes of ischemic stroke patients. A total of 355 patients who had experienced ischemic stroke participated in inflammatory cytokine detection by ELISA, in addition to depression, quality of life (QOL) and body performance testing. Cox regression was used to evaluate the associations between PSD risk, inflammatory cytokines and the outcomes of patients. Measurement data was evaluated using Student's t test, and counted data was measured by χ2 test. The incidence of PSD during the 2-year follow-up was 23.1%. The risk of PSD elevated with increased interleukin (IL)-6 expression levels [hazard ratio (HR)=3.18; 95% confidence interval (CI), 1.37-7.36] following the adjustment of confounders. However, no significant associations were identified between PSD and other inflammatory cytokines. QOL and body performance in the depressed group were significantly worse compared with those in the non-depressed group. The risk of stroke recurrence in patients with depression increased two-fold compared with patients without depression (HR=2.020; 95% CI, 1.123-3.635; Ptrend=0.019). No significant associations between PSD and the risk of mortality (HR=1.497; 95% CI, 0.547-4.098) were observed. In conclusion, depression is prevalent in patients following ischemic stroke. IL-6 is positively associated with the risk of PSD, and may predict its development in patients following ischemic stroke. PSD correlates with outcomes of patients, and the effective management of PSD may improve the prognosis of patients.

4.
Mol Med Rep ; 13(5): 3763-70, 2016 May.
Article in English | MEDLINE | ID: mdl-27035875

ABSTRACT

It has previously been demonstrated that curcumin possesses an antitumor activity, which is associated with its ability to induce G2/M cell cycle arrest and apoptosis. However the detailed underlying mechanisms remain unclear. The present study aimed to investigate the efficacy and underlying mechanism of curcumin­induced cell cycle arrest and apoptosis in U87 human glioblastoma cells. By immunofluorescence staining, subcellular fractionation and western blotting, the present study demonstrated that curcumin was able to induce G2/M cell cycle arrest and apoptosis by increasing the expression levels of cyclin G2, cleaved caspase­3 and Fas ligand (FasL), and decreasing the expression of cyclin­dependent kinase 1 (CDK1). In addition, increased expression of forkhead box protein O1 (FoxO1) and decreased expression of phosphorylated (p)­FoxO1 were detected in the curcumin­treated U87 cells. Curcumin was also able to induce the translocation of FoxO1 from the cytoplasm to the nucleus. Furthermore, following knockdown of FoxO1 expression in curcumin­treated U87 cells using FoxO1 small interfering RNA, the expression levels of cyclin G2, cleaved caspase­3 and FasL were inhibited; however, the expression levels of CDK1 were not markedly altered. Notably, following knockdown of CDK1 expression under normal conditions, the total expression of FoxO1 was not affected; however, p­FoxO1 expression was decreased and FoxO1 nuclear expression was increased. Furthermore, curcumin­induced G2/M cell cycle arrest and apoptosis could be attenuated by FoxO1 knockdown. These results indicated that curcumin may induce G2/M cell cycle arrest and apoptosis in U87 cells by increasing FoxO1 expression. The present study identified a novel mechanism underlying the antitumor effects of curcumin, and may provide a theoretical basis for the application of curcumin in glioma treatment.


Subject(s)
Apoptosis/drug effects , Curcumin/pharmacology , Forkhead Box Protein O1/biosynthesis , G2 Phase Cell Cycle Checkpoints/drug effects , Gene Expression Regulation, Neoplastic/drug effects , Glioma/metabolism , M Phase Cell Cycle Checkpoints/drug effects , Neoplasm Proteins/biosynthesis , Signal Transduction/drug effects , Cell Line, Tumor , Glioma/drug therapy , Glioma/pathology , Humans
5.
J Neurooncol ; 124(3): 475-84, 2015 Sep.
Article in English | MEDLINE | ID: mdl-26215876

ABSTRACT

Depression is found to be associated with up-regulation of inflammatory cytokines. However, the relationship in high grade glioma (HGG) patients is still unclear. In this prospective study, a total 132 HGG patients participated in blood sample collection for inflammatory cytokines detection by ELISA, mental status, quality of life (QOL) and physical functional status testing. The association between inflammatory cytokines and depression risk was assessed using conditional logistic regression. The incidences of depressive symptoms and depression in high grade glioama patients were 45.5 and 25 % respectively during 12 months follow-up. We found the risk of depression was elevated with increased C-reactive protein (CRP) and interleukin-6 (IL-6) in high grade glioma patients after adjustment of confounders. The serum levels of CRP and IL-6 in patients with transient depression and depression were higher than those without depressive symptoms. In addition, depression had significant effects on the survival, QOL and physical functional status of patients. Depression is prevalent among patients with HGG. The present study suggests that serum CRP and IL-6 may serve as a depression marker for HGG patients. The survival and quality of life of HGG patients may be improved by an effective management for depression.


Subject(s)
Brain Neoplasms/complications , Brain Neoplasms/metabolism , Cytokines/blood , Depression/etiology , Glioma/blood , Glioma/complications , Aged , C-Reactive Protein/metabolism , Enzyme-Linked Immunosorbent Assay , Female , Humans , Karnofsky Performance Status , Male , Middle Aged , Prognosis , Prospective Studies , Psychiatric Status Rating Scales , Quality of Life
6.
Med Oncol ; 31(10): 234, 2014 Oct.
Article in English | MEDLINE | ID: mdl-25223530

ABSTRACT

To date, the relationship between metabolic syndrome factors and the risk of glioma-related depression is still unclear, and no study investigates this relationship. Our aim was to investigate the relationship between metabolic syndrome factors and the risk of postoperative depression in high-grade patients. A total of 386 high-grade glioma patients participated in blood sample collection for metabolic syndrome factors analysis and the hospital anxiety and depression scale testing. The association between metabolic syndrome factors and the risk of postoperative depression was assessed using Cox regression proportional hazards models, and Student's t tests were used to evaluate the differences in demographic variables and clinical characteristics in subgroups. The incidence of postoperative depression in our 1.5-year follow-up was 30.5%. We found the risk of postoperative depression was elevated with increased blood glucose level [hazard ratios (HR) 2.277, 95% confidence interval (CI) 1.201-4.320, top vs. bottom quartile]. The hazard ratio was increased for z-scores of blood glucose (HR 1.672 per unit standard deviation, 95% CI 1.311-2.133] and of the combined metabolic syndrome score (HR 1.080, 95% CI 1.000-1.167). In addition, risk of postoperative depression risk was increased in high-grade glioma patients with high blood glucose levels (≥6.0 mmol/l) (HR 2.084, 95% CI 1.235-3.515). However, we did not find significant associations between postoperative depression and other metabolic syndrome factors, including body mass index, systolic blood pressure, diastolic blood pressure, cholesterol, and triglycerides. Depression is prevalent among patients with high-grade glioma after operation. Blood glucose level is positively associated with the risk of postoperative depression, and might be involved in the etiology of postoperative depression, and may predict its development in high-grade glioma patients.


Subject(s)
Brain Neoplasms/surgery , Depressive Disorder/etiology , Glioma/surgery , Metabolic Syndrome/diagnosis , Postoperative Complications , Adult , Aged , Blood Pressure , Body Mass Index , Cholesterol/blood , Depressive Disorder/diagnosis , Female , Humans , Intelligence Tests , Male , Middle Aged , Prospective Studies , Risk Factors , Surveys and Questionnaires , Triglycerides/blood
7.
Neurosci Lett ; 536: 41-6, 2013 Mar 01.
Article in English | MEDLINE | ID: mdl-23328441

ABSTRACT

Necroptosis was reported as one backup way of programmed cell death when apoptosis was blocked, and the receptor interacting protein 1 was considered as the key necroptosis regulator protein. Here, we report the neuroprotective effects of curcumin which attenuates necroptosis. Primary cortical neurons were cultured and were injured by ferrous chloride, z.vad.fmk was applied to block apoptosis, curcumin was administrated to protect neurons, necrostatin-1 was applied to inhibit necroptosis if needed. Cell viability was measured by detecting lactate dehydrogenase activity in lysates of surviving cells, and assessed by cell counting kit-8. The expression of receptor interacting protein 1 was detected by immunoblot and immunofluorescence. Results showed that necroptosis mainly occurred in the concentrations of ferrous chloride ranging from 100 to 200µM, curcumin attenuated necroptosis in a dose-dependent manner. Furthermore, curcumin decreased expression of receptor interacting protein 1 in a dose- and time-dependent manner. Taken together, these findings suggest that curcumin protects against iron induced neurotoxicity in primary cortical neurons by attenuating necroptosis.


Subject(s)
Cerebral Cortex/drug effects , Curcumin/pharmacology , Iron Overload/pathology , Neurons/drug effects , Neuroprotective Agents/pharmacology , Animals , Apoptosis , Cells, Cultured , Cerebral Cortex/pathology , Dose-Response Relationship, Drug , Embryo, Mammalian/cytology , Ferrous Compounds/toxicity , Iron Overload/prevention & control , Mice , Mice, Inbred C57BL , Necrosis , Neurons/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...